Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Mirikizumab & Crohn's disease (CD), the US FDA has approved Mirikizumab for the treatment of moderately to severely active Crohn's disease (CD) in adults (1)
The randomized clinical phase III treatment trial, known as NCT03926130 (VIVID-1), demonstrated that Mirikizumab is both safe and effective for use as an induction and maintenance treatment in patients suffering from moderately-to-severely active Crohn's disease. This is particularly relevant for those who have experienced intolerance, an inadequate response, or a loss of response to standard therapy (2).
(1) [fda-approves-eli-lilly-omvoh-crohns-disease-phaseiii-vivid1-trial](https…